What Is Dordaviprone?
Dordaviprone (Brand name: Modeyso) is a prescription medicine used to treat adults and children 1 year of age and older with a rare type of brain tumor called diffuse midline glioma (a rare, but quickly advancing, aggressive brain tumor) that has an H3 K27M gene mutation and has worsened after other treatments.
H3 K27M refers to a gene mutation, or specific 'error' or change in the DNA of tumor cells that makes this kind of brain tumor grow.
Dordaviprone belongs to a drug class called monoclonal antibodies (mah-nuh-KLOH-nul anti-BOD-eez), which targets proteins in certain brain tumors, slowing tumor growth.
Who Can Take It?
Adults and pediatric patients a year old or younger with confirmed tumor and disease progression.
Common Side Effects
- Tiredness, nausea, vomiting, headache
- Muscle, joint, or bone pain
- Low white or red blood cells, low calcium
- Elevated liver enzymes
Serious side effects may include:
- Allergic reaction: rash, swelling of face or throat, hives, wheezing, dizziness, fever
- Heart rhythm changes: lightheadedness, palpitations, fast heartbeat, fainting
- Neurologic: severe headache, confusion, slurred speech, limb weakness, stiff muscles, high fever, tremors
- Eye problems: sudden vision loss, blurred or tunnel vision, eye pain, halos around lights
Drug Interactions
| Feature | Vorasidenib | Voranigo (vorasidenib) |
Avastin (bevacizumab) |
Modeyso (dordaviprone) |
|---|---|---|---|---|
| Prescription Only? | Yes | Yes | Yes | Yes |
| Primary Indication | Malignant glioma with H3 K27M mutation |
Malignant glioma with H3 K27M mutation |
Multiple cancers (e.g., colorectal, glioblastoma) |
Diffuse midline glioma with H3 K27M mutation |
| Dosing (Adult) | 100 mg once daily* | 100 mg once daily* | 10 mg/kg IV every 2 weeks† | 625 mg once weekly (≥ 115.7 lb) |
| Route | Oral capsule | Oral capsule | IV infusion | Oral capsule |
| *Example dosing—see full prescribing information. †Typical bevacizumab dosing varies by indication. | ||||
- Drugs to Avoid:
- Avoid strong/moderate inhibitors (e.g., certain antifungals, antibiotics) or inducers (e.g., rifampin). If unavoidable, adjust dose in patients ≥ 115.7 lb.
- Other QT-prolonging drugs: avoid or separate dosing to lower risk of arrhythmias.
Warnings & Precautions
Warnings & Precautions may include:
- Hypersensitivity: can cause severe reactions—stop therapy if anaphylaxis occurs.
- Embryo-fetal toxicity: use effective contraception during and 1 month after therapy (all patients of reproductive potential).
- Fertility risk: may impair fertility in males and females.
Pregnancy & Lactation
- During pregnancy: may cause fetal harm—confirm non-pregnant status before therapy.
- Breastfeeding: no data on presence in human milk—avoid breastfeeding during and 1 week after therapy.
Monitoring & Follow-Up
- Report side effects to your doctor or FDA: 800-FDA-1088.
This guide is intended for informational purposes only and is not a substitute for professional medical advice.
